Table 1 Clinical characteristics between patients with and without DMRGM
Variables | Total n = 843 (%) | DMRGM (+) n = 250 (%) | DMRGM (-) n = 593 (%) | P value |
|---|---|---|---|---|
Gender | Â | Â | Â | 0.686 |
 Male | 444 (52.7) | 129 (51.6) | 315 (53.1) |  |
 Female | 399 (47.3) | 121 (48.4) | 278 (46.9) |  |
Age, years |  |  |  |  < 0.001 |
 Median (Range) | 43 (9–78) | 49 (10–78) | 39 (9–74) |  |
WBC count, *109/L | Â | Â | Â | 0.044 |
 Median (Range) | 14.2 (0.1–406.9) | 18.1 (0.5–383.8) | 13.8 (0.1–406.9) |  |
Hemoglobin, g/L | Â | Â | Â | 0.979 |
 Median (Range) | 85 (33–171) | 85 (34–140) | 85 (33–171) |  |
Platelet count, *109/L |  |  |  |  < 0.001 |
 Median (Range) | 42 (2–713) | 55 (4–713) | 37 (3–376) |  |
Karyotype |  |  |  |  < 0.001 |
 Favorable | 102 (12.1) | 8 (3.2) | 94 (15.9) |  |
 Intermediate | 617 (73.2) | 208 (83.2) | 409 (69.0) |  |
 Adverse | 91 (10.8) | 19 (7.6) | 72 (12.1) |  |
 Unknown | 33 (3.9) | 15 (6.0) | 18 (3.0) |  |
2017 ELN | Â | Â | Â | 0.014 |
 Favorable | 357 (42.3) | 99 (39.6) | 258 (43.5) |  |
 Intermediate | 236 (28.0) | 87 (34.8) | 149 (25.1) |  |
 Adverse | 250 (29.7) | 64 (25.6) | 186 (31.4) |  |
Induction therapy | Â | Â | Â | 0.001 |
 Standard therapy | 477 (56.6) | 117 (46.8) | 360 (60.7) |  |
 Low intensity | 308 (36.5) | 114 (45.6) | 194 (32.7) |  |
 Others | 58 (6.9) | 19 (7.6) | 39 (6.6) |  |
Response to first induction therapya | Â | Â | Â | 0.014 |
 CR/CRi | 566 (67.9) | 149 (60.3) | 417 (71.0) |  |
 PR | 102 (12.2) | 33 (13.4) | 69 (11.8) |  |
 NR | 147 (17.6) | 58 (23.5) | 89 (15.2) |  |
 Early death | 19 (2.3) | 7 (2.8) | 12 (2.0) |  |
Transplant | Â | Â | Â | 0.079 |
 Yes | 474 (56.2) | 129 (51.6) | 345 (58.2) |  |
 No | 369 (43.8) | 121 (48.4) | 248 (41.8) |  |